Labcorp Q3 revenue $3.28B, adj EPS $3.50 vs $3.38; lowers FY adj EPS midpoint $0.10

LABCORP HOLDINGS INC.

2024-Q3 EPS reported $7.13 revenue$9,679,500,000

Revenue $3.28B (+7.4% YoY); diluted EPS from cont ops $2.00 vs $2.11; adj EPS $3.50 vs $3.38.
FY 2024 adj EPS midpoint lowered $0.10 to $14.30-$14.70 on ~$0.15 weather hit; FCF $161.5M.
Diagnostics revenue $2.55B (+8.9% YoY), base business organic 5.7%; Biopharma rev $737.7M (+2.6%).
Announced acquisitions of Ballad Health outreach assets, Lab Works, and Naples lab mgmt; closed Invitae and BioReference Health purchases.
Quarterly dividend $0.72/share declared, payable Dec 13, 2024 to holders of record Nov 26, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.